Current prostate Ca guidelines miss germline variants
October 4th 2017Adherence to current guidelines for genetic testing in men with prostate cancer would miss a sizable proportion of patients with pathogenic germline variants, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Robotic vs. open RP: Better EF recovery seen with robot
October 1st 2017Robot-assisted radical prostatectomy was associated with earlier and increased rate of recovery of erectile function when compared to radical retropubic prostatectomy and a slightly higher but acceptable rate of positive surgical margins, according to a study published online in European Urology (Sept. 4, 2017).
Prostate Ca study reveals more evidence of racial disparity
September 6th 2017Results of a study examining receipt of definitive therapy for intermediate/high-risk localized prostate cancer provide further evidence of racial disparity in prostate cancer favoring Caucasian men over African-American men.
Prostate MRI has value, but results are not ‘gospel’
September 1st 2017Magnetic resonance imaging (MRI) of the prostate may be used in many clinical scenarios, including primary screening, active surveillance, and in patients with a previous negative biopsy and rising PSA. In this interview, Scott Eggener, MD, explains whether MRI is warranted in each of these situations and the benefits and challenges this technology presents.
Prostate MRI-Bx may ID partial gland ablation candidates
September 1st 2017Information from magnetic resonance imaging and systematic biopsy may be used to identify candidates for partial gland ablation among men with recurrent localized prostate cancer after radiation therapy, researchers from Memorial Sloan Kettering Cancer Center reported at the AUA annual meeting in Boston.
Fusion Bx-guided HIFU shows promise in localized PCa
September 1st 2017Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.
ADT plus salvage RT lowers PCa metastases, raises survival
September 1st 2017A recent review of two phase III randomized controlled trials demonstrated that addition of androgen deprivation therapy to salvage pelvic radiation therapy for prostate cancer recurrence after radical prostatectomy reduces the risk of metastases and improves overall survival.
How prostate cancer genetics will change front-line care
August 1st 2017In this interview, Leonard G. Gomella, MD, provides an update on prostate cancer genetics, discusses the recent Prostate Cancer International Consensus Conference, and outlines why urologists should conduct more extensive family histories of their prostate cancer patients.
Side effects of modern PCa treatments compared
August 1st 2017Despite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.
Higher reclassification rate seen with saturation biopsy
July 1st 2017Transrectal saturation biopsy resulted in higher rates of disease reclassification compared with magnetic resonance (MR) fusion biopsy plus extended sextant prostate biopsy in patients with low-risk prostate cancer on active surveillance.